KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Retained Earnings: 2009-2025

Historic Retained Earnings for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $502.1 million.

  • Halozyme Therapeutics' Retained Earnings rose 26.29% to $502.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.1 million, marking a year-over-year increase of 26.29%. This contributed to the annual value of $359.9 million for FY2024, which is 297.43% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Retained Earnings stood at $502.1 million, which was up 39.09% from $361.0 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Retained Earnings registered a high of $502.1 million during Q3 2025, and its lowest value of -$433.7 million during Q1 2021.
  • For the 3-year period, Halozyme Therapeutics' Retained Earnings averaged around $276.9 million, with its median value being $260.6 million (2024).
  • Over the last 5 years, Halozyme Therapeutics' Retained Earnings had its largest YoY gain of 2,453.78% in 2023, and its largest YoY loss of 36.77% in 2023.
  • Halozyme Therapeutics' Retained Earnings (Quarterly) stood at -$58.9 million in 2021, then skyrocketed by 343.10% to $143.2 million in 2022, then plummeted by 36.77% to $90.5 million in 2023, then skyrocketed by 297.43% to $359.9 million in 2024, then climbed by 26.29% to $502.1 million in 2025.
  • Its Retained Earnings was $502.1 million in Q3 2025, compared to $361.0 million in Q2 2025 and $478.0 million in Q1 2025.